Next Phase Newsletter

A healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in Boston and London, the firm is primarily looking for companies throughout North America and Europe. 
 
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications. 
 
The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly formed subsidiary of a hedge fund is based in the US. The firm is interested in healthcare and data looking to build predictive disease risk models and has dedicated USD $20M to make investments to early-stage startups in Pre-Seed to Series A rounds. Initial check sizes can go up to USD $2M and the firm can lead or co-invest. The firm does not have geographical restrictions, however, prefers the U.S. and Europe. 
 
The firm is interested in diagnostics and health-tech companies. Specifically, the firm would like to see technologies that allow people to understand and quantify their health including, but not limited to, technologies that help analyze health data, applications and algorithms, mobile applications, and technologies that cater to the medical community to increase work efficiency. The firm would like to see a working prototype that is somewhat validated. 
 
The firm may take a board seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private investment firm currently manages approximately several billion in capital and looks to make controlling equity investments into companies anywhere from a few million dollars and up depending on the financial needs and stage of the company. The firm is interested in companies located around the globe. 
 
The firm is looking for companies in the life science space including Pharmaceuticals, Biologics, Medical Devices and Services/Technology though the firm’s primarily interest is in Therapeutics. The firm will consider investments into companies from Seed and Venture stage to those that already have a product on the market. The firm is agnostic in terms of subsector/indication and is also open to orphan indications. 
 
The firm will look at companies with scientific founding management teams as well as more developed companies with complete management teams in place. The firm looks to provide strategic support through its sector-specific expertise and flexible financing to build exceptional businesses. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm typically engages in pre-seed to seed round investments. The initial check size ranges from $500k to $1M, with follow-on investments possible. While the firm prefers to lead, it is open to syndicating deals. The firm invests in both Europe and the US. 
 
The team has strong backgrounding software, AI, and algorithm. Within life sciences and healthcare, the firm is looking into tech bio, synthetic biology, computational biology, chemistry, and materials. The firm is open to hardware (diagnostics or medical device) that enables new data modalities with software insights, digital health, and therapeutic platforms, but not traditional therapeutic assets. It is indication agnostic. In terms of development stages, the firm is willing to consider opportunities as early as the pre-prototype stage, provided there are plans for patent or IP protection. 
 
There are no specific requirements for the company or the management team. However, the firm prefers technical founders with a strong scientific background. The firm will consider taking a board seat or an observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early-stage investment and development firm located in the US operates under an evergreen structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-10M range and the firm reserves additional funds for the subsequent funding of successful companies. 

 
The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics and have multi-million dollar yearly sales. 
 
The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider certain opportunities in Europe. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in the US is currently investing from their 1st fund. The firm invests in Seed and Series A. The firm makes initial equity investments between $250K-$3M. The firm prefers to lead and requires a board seat; however, they can co-invest as well. The firm invests in the USA and will consider investments outside of the USA if a regulatory process has been completed. 
 
The firm invests in healthtech, medtech, and techbio. The firm has a particular consideration for IVD. For digital health (considered healthtech), the firm prefers software-based solutions, and has an overall investment focus on software-based solutions. For tech bio, the firm is interested in tech such as gene editing and cell therapies. For diagnostics and medical devices, the firm will only invest in class 1 and 510K and is not open to PMA. The firm requires companies to be revenue generating, indicating scale and likes to see annual repeat customers. 
 
The firm prefers to lead and requires a board seat. The firm is founder friendly and has no strict management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients has broad expertise in development sciences, delivery technologies, and multi-modality manufacturing. The firm is a preferred partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The firm has launched a joint venture investment fund to invest strategically in early-stage startups and platforms. By investing in new technologies, partnering with innovators through co-development and in-licensing, across the academic and industry, the firm helps to bring disruptive innovation to the market. The firm invests globally but has primarily partnered with companies in North America and Europe to date. 
 
The firm invests in technology-enabled platform life sciences companies that are relevant to its science and technology and corporate innovation initiatives. Illustrative potential investments include next-generation biomanufacturing platforms, drug delivery platforms, drug-device combinations, cell-line engineering, mAb discovery, development tools, and inputs. The firm will consider investing in companies advancing therapeutic assets if they are also developing platforms technologies. 
 
The firm can lead or co-invest, and while it considers a board seat a plus, it is not a requirement after investing. The firm values the experience of serial entrepreneurs when partnering and focuses on strategic and deeper relationships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.